Drugs / HBS-301
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07675135 | Jun 2026 → Oct 2027 expected | narcolepsy-cataplexy syndrome | Harmony Biosciences Management, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07500090 | Mar 2026 → Oct 2027 expected | idiopathic hypersomnia | Harmony Biosciences Management, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBS-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07500090 ↗ |
| Route | Oral | “HBS-301 tablets administered once daily in the morning upon wakening” NCT07500090 ↗ |